Would you trust a complementary medicine described as “vermifuge”, “vulnerary” or “emmenagogue”? That’s what new labelling proposes and not everyone’s happy about it.
Academic rigour, journalistic flair
Articles on Therapeutic Goods Administration
Displaying 21 - 35 of 35 articles
Regulatory bodies approved some medical devices to treat pelvic organ prolapse and urinary incontinence before having data to prove their safety and efficacy.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
If the Therapeutic Goods Administration implements new proposals to regulate complementary medicines, you can be more confident they actually do what they say on the packet.
The recent decision to effectively ban e-cigarettes will hurt poor and disadvantaged smokers the most.
E-cigarettes remain effectively banned in Australia because advocates’ evidence has failed to convince the Therapeutic Goods Administration.
Consumers can’t always be confident claims for complementary medicines stack up. Here’s how to foster truth in advertising.
Classing e-cigarettes as quit smoking aids could help rebrand the tobacco industry as a legitimate player in health policy. Here’s why we should be concerned.
Should new understandings of how cancers develop and could be targeted mean we should change the way the scheme registers cancer drugs?
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
The off-label use of medicines is not illegal and it doesn’t mean regulators have specifically “disapproved” its use. But there are a number of issues to consider before using a medicine off-label.
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
The latest part of the TPP to be leaked is its investment chapter. And like almost everything we know about the secretive negotiations for the agreement, it provides plenty of cause for concern.
One of the much-heralded platforms of the Abbott government is its promise to business to reduce red tape and burdensome regulatory obligations. Pharmaceuticals are a multi-billion dollar global industry…
I submitted a complaint about the promotion of “FatBlaster Reducta” (ARTG no: 176366) to the Therapeutic Goods Administration in March 2011. The product is a “complementary medicine” containing an extract…
Job Board
-
Associate Professor, Occupational Therapy
-
GRAINS RESEARCH AND DEVELOPMENT CORPORATION CHAIRPERSON
-
Technical Skills Laboratory Officer
-
Faculty of Law - Academic Appointment Opportunities
-
Audience Development Coordinator (fixed-term maternity cover)
Top contributors
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Health activist, Medreach Pty Ltd., Bond University
-
Associate Professor, School of Law, University of Canberra
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Head of School and Dean of Pharmacy, University of Sydney
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Pharmacist and PhD Candidate, University of Sydney
-
Associate Professor in Public Health, La Trobe University
-
Emeritus Professor in Public Health, University of Sydney
-
Senior lecturer, University of South Australia
-
Vice Chancellor’s Senior Research Fellow, Social Equity Research Centre and Digital Ethnography Research Centre, RMIT University
-
Canada Research Chair in Economy and Environment, Queen's University, Ontario
-
Senior Lecturer of Addiction, Edith Cowan University
-
Director, School of Regulation and Global Governance (RegNet) and Professor of Health Equity, ANU, Australian National University
-
Adjunct Senior Lecturer, Centre for Primary Health Care and Equity, University of New South Wales, UNSW Sydney
